ERBB2 and non-small cell lung carcinoma: Importantly, a lower rate of lung toxicity for patients treated with T-DM1 has been confirmed for NSCLC patients, with 0 cases of pneumonitis observed in 49 patients with HER2-positive NSCLC treated with T-DM1 in a phase 2 study [45].